Details of the Drug
General Information of Drug (ID: DM1MRFW)
| Drug Name |
NSC-119911
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
NSC119911; CHEMBL258670; CHEMBL3260988; NSC-119911; MLS-0111616.0001; AC1OBGP2; AC1NTI1U; AC1NS1JN; SCHEMBL2846330; SCHEMBL2846323; CHEMBL502775; (9Z)-9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; ZINC3954334; BDBM50011357; NSC158917; NCI119911; CCG-36604; BDBM50373125; NSC-158917; 9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; (E)-3-(3,4,5-trihydroxy-6-oxo-xanthen-9-yl)prop-2-enoic acid; 2-Propenoic acid, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-, (2E)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 314.25 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.7 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


